MAXIMIZING ONCOLOGY EXPLORATION WITH BUILT-IN KRAS ASSAY SOLUTIONS AND RAS ASSAYS

during the promptly evolving subject of oncology investigation, correct and productive mutation screening is important for building targeted therapies. The KRAS solutions Platform plays a pivotal role During this landscape by providing complete methods for KRAS mutation profiling and Examination. KRAS mutations, present in around 95% of RAS-linked